TR200101445T2 - Kararlı, zayıflatılmış kuduz virüsü mutantları ve bu mutantların canlı aşıları - Google Patents

Kararlı, zayıflatılmış kuduz virüsü mutantları ve bu mutantların canlı aşıları

Info

Publication number
TR200101445T2
TR200101445T2 TR2001/01445T TR200101445T TR200101445T2 TR 200101445 T2 TR200101445 T2 TR 200101445T2 TR 2001/01445 T TR2001/01445 T TR 2001/01445T TR 200101445 T TR200101445 T TR 200101445T TR 200101445 T2 TR200101445 T2 TR 200101445T2
Authority
TR
Turkey
Prior art keywords
mutants
codon
rabies virus
stable
live vaccines
Prior art date
Application number
TR2001/01445T
Other languages
English (en)
Inventor
Mebatsion Teshome
Klaus Conzelmann Karl
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of TR200101445T2 publication Critical patent/TR200101445T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Bu bulus, viral genom içinde bir mutasyonu içeren rekombinant kuduz virüsü mutantlarina iliskindir, bulusta, bahsedilen mutasyon, G proteinini kodlayan gendeki Arg333 kodonunun, bahsedilen Arg333 kodonundan üç nükleotid ile farkli olan bir kodon ile en azindan bir ikamesini içermektedir. Bu kuduz virüsü mutantlari, parental virüsün glikoproteininde 333 amino asidi konumunda Arg kodonundan üç nükleotidin tümü ile farklilik tasiyan bir kodon ile kodlanmis, 333 konumunda bir amino asidini içeren bir G glikoproteininine sahiptir. Bahsedilen rekombinant kuduz virüs mutantlari bagisiklik rekabetçi hayvanlarinda kararlidir ve patojenik degildir ve bir canli, zayiflatilmis anti-kuduz asisinda kullanim için müsaittir.
TR2001/01445T 1998-11-27 1999-11-19 Kararlı, zayıflatılmış kuduz virüsü mutantları ve bu mutantların canlı aşıları TR200101445T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98204001 1998-11-27

Publications (1)

Publication Number Publication Date
TR200101445T2 true TR200101445T2 (tr) 2001-10-22

Family

ID=8234392

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01445T TR200101445T2 (tr) 1998-11-27 1999-11-19 Kararlı, zayıflatılmış kuduz virüsü mutantları ve bu mutantların canlı aşıları

Country Status (16)

Country Link
US (1) US6719981B1 (tr)
EP (1) EP1131414B1 (tr)
AR (1) AR021406A1 (tr)
AT (1) ATE356202T1 (tr)
AU (1) AU1386100A (tr)
BR (1) BR9915703B1 (tr)
CA (1) CA2352231C (tr)
CY (1) CY1106570T1 (tr)
DE (1) DE69935445T2 (tr)
DK (1) DK1131414T3 (tr)
ES (1) ES2283150T3 (tr)
ID (1) ID28968A (tr)
IL (2) IL143149A0 (tr)
PT (1) PT1131414E (tr)
TR (1) TR200101445T2 (tr)
WO (1) WO2000032755A1 (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1253197B1 (en) * 2001-04-23 2006-01-25 Akzo Nobel N.V. Attenuated recombinant rabies virus and live vaccines thereof
KR20040029377A (ko) 2001-07-20 2004-04-06 더 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 공수병의 예방 접종 및 중추신경계 질환의 유전자 요법을위한 인산화 부위의 핵단백질 돌연변이를 갖는 약독화공수병 바이러스
BRPI0617373B1 (pt) 2005-10-14 2022-04-05 The Goverment of The United States of America, Representado por, The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention Composições e métodos do vírus da raiva
US7785874B2 (en) * 2007-01-11 2010-08-31 The Salk Institute For Biological Studies Compositions and methods for monosynaptic transport
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
DK2670843T3 (en) 2011-02-03 2015-01-05 Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services MULTIVALENT VACCINES FOR RABIES VIRUS AND FILOVIRUS
CN103865889B (zh) * 2014-04-03 2015-02-25 深圳市卫光生物制品股份有限公司 狂犬病病毒ctn鸡胚细胞适应株
US11041170B2 (en) 2016-04-04 2021-06-22 Thomas Jefferson University Multivalent vaccines for rabies virus and coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2580176B1 (fr) * 1985-04-12 1988-02-26 Centre Nat Rech Scient Vaccin antirabique avirulent
FR2633832B1 (fr) * 1988-07-05 1991-05-31 Virbac Vaccin antirabique avirulent
FR2693655B1 (fr) * 1992-07-20 1994-10-14 Virbac Vaccin antirabique avirulent.
SE0002498D0 (sv) 2000-07-03 2000-07-03 Stefan Schwartz Papillomavirus vaccine
AU2002360311A1 (en) 2001-12-10 2003-06-23 Donaldson Company, Inc. Exhaust treatment control system for an internal combustion engine
DE102004009653A1 (de) 2004-02-27 2005-09-22 Cycos Ag Kommunikationsserver und Verfahren zum Aufbau und Betrieb einer Konferenz-Kommunikationsverbindung

Also Published As

Publication number Publication date
EP1131414B1 (en) 2007-03-07
BR9915703A (pt) 2001-08-14
AU1386100A (en) 2000-06-19
US6719981B1 (en) 2004-04-13
EP1131414A1 (en) 2001-09-12
ATE356202T1 (de) 2007-03-15
ID28968A (id) 2001-07-19
BR9915703B1 (pt) 2012-09-04
DE69935445D1 (de) 2007-04-19
IL143149A (en) 2007-12-03
CA2352231C (en) 2010-06-01
ES2283150T3 (es) 2007-10-16
WO2000032755A1 (en) 2000-06-08
DK1131414T3 (da) 2007-06-18
CY1106570T1 (el) 2012-01-25
IL143149A0 (en) 2002-04-21
AR021406A1 (es) 2002-07-17
DE69935445T2 (de) 2007-11-29
CA2352231A1 (en) 2000-06-08
PT1131414E (pt) 2007-04-30

Similar Documents

Publication Publication Date Title
DE69937999D1 (de) Interferon induzierende genetisch veränderte attenuierte viren
RU2733832C1 (ru) Искусственный ген Stbl_RBD_TrM_SC2, кодирующий бицистронную структуру, образованную последовательностями рецепторсвязывающего домена гликопротеина S коронавируса SARS-CoV-2, трансмембранного региона, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_TrM_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_TrM_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
CA2074502C (en) Vaccines
DK1114189T3 (da) Rekombinante Newcastle disease virus RNA ekspressionssystemer og vacciner
CY1106570T1 (el) Σταθερες, εξασθενημενες μεταλλαγμενες μορφες ιου λυσσας και ζωντανια εμβολια αυτων
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
EP0261940A3 (en) Pseudorabies vaccines and dna vectors for recombination with pox viruses
WO2004106360A3 (en) Viral vectors with improved properties
JP2004524805A5 (tr)
IL168374A (en) Vaccines against west nile virus
YU80500A (sh) Vakcina izazvana sojem virusa hepatitisa b i njeno dobijanje
ATE223492T1 (de) Mutanten des infektiösen rinder rhinotracheitis- virus und impfstoffe
TR200201081A2 (tr) Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları
TR200102168T2 (tr) BHV-1 geni silinmiş virüs aşısı.
WO1999057284A3 (en) Attenuated influenza viruses
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS
CA2351010A1 (en) A broad spectrum infectious bursal disease virus vaccine
Skoging-Nyberg et al. A conserved leucine in the cytoplasmic domain of the Semliki Forest virus spike protein is important for budding
TR200003777T2 (tr) Mutant bir insan hepatit B virüsü türü ve bunun kullanımı
KR960040374A (ko) 매우 약독화된 일본 뇌염 비루스를 생성하는 감염성 일본 뇌염 비루스 cDNA 클로 및 이의 백신
RU2021109330A (ru) Химерные вакцины на основе вирусов родов flavivirus и lyssavirus
NZ607667A (en) Influenza viruses able to infect canids, uses thereof
TH62970A (th) วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)
JP2010248179A (ja) 医薬組成物
TH44158A3 (th) สายพันธุ์ไวรัสตับอักเสบชนิด b ที่เหนี่ยวนำให้เกิดขึ้นโดยวัคซีนและการใช้งานของสายพันธุ์ดังกล่าว